← Browse by Condition
Medical Condition

acute ischemic stroke ais

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 3, Phase 2

Stroke trials address both acute treatment (revascularization within hours of onset) and long-term secondary prevention, with rehabilitation science emerging as a distinct research priority. Advances in thrombectomy techniques have dramatically improved outcomes for large vessel occlusion strokes, driving trials to push the treatment window from 6 to 24 hours in selected patients.

Current research includes tenecteplase vs alteplase for thrombolysis, thrombectomy for medium vessel occlusions, neuroprotective agents, factor XIa inhibitors for secondary prevention with lower bleeding risk, and telerehabilitation using robotics and brain-computer interfaces. Trials in wake-up stroke and unknown time-of-onset have expanded using MRI mismatch criteria.

Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Penumbra Inc. 1 trial
University of Calgary 1 trial
Euphrates Vascular, Inc. 1 trial
Prof. Dr. Jan Liman 1 trial
Shenzhen Wingor Biotechnology Co., Ltd. 1 trial
NCT07107022
Recruiting

Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

Enrollment
200 pts
Location
Australia, France, G...
Sponsor
Penumbra Inc.
View Trial →
NCT06320431 Phase 3
Recruiting

ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Enrollment
4,000 pts
Location
Australia, Canada
Sponsor
University of Calgary
View Trial →
NCT06052969
Recruiting

Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

Enrollment
8 pts
Location
United States
Sponsor
Euphrates Vascular, Inc.
View Trial →
NCT07052045
Recruiting

One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy

Enrollment
390 pts
Location
Germany, Switzerland
Sponsor
Prof. Dr. Jan Liman
View Trial →
NCT07084012 Phase 2
Recruiting

A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS

Enrollment
60 pts
Location
China
Sponsor
Shenzhen Wingor Biotechnology ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology